The role of VWF for the success of immune tolerance induction

Thrombosis Research

Volumn 122, Issue SUPPL. 2, 2008, Pages

  Kreuz, Wolfhart ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Factor VIII (FVIII); FVIII inhibitors; Haemophilia A; Immune tolerance induction (ITI); von Willebrand factor (VWF)

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; VON WILLEBRAND FACTOR;

ARTHROPATHY; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; COST CONTROL; HEMOPHILIA; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; QUALITY OF LIFE;

FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; VON WILLEBRAND FACTOR;

EID: 44649136183     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(08)70003-3     Document Type: Article

References (22)

1. Berntorp E., Ekman M., Gunnarsson M., and Nilsson I. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations. Haemophilia 2 (1996) 95-99
2. Kreuz W., Joseph-Steiner J., Mentzer D., Auerswald G., Beeg T., and Becker S. Successful immunetolerance therapy of F VIII-inhibitor in children after changing from high to intermediate purity F VIII concentrate. Ann Hematol 72 Suppl 1 (1996) A85
3. Leissinger C. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 77 (2004) 187-193
4. Lillicrap D. The role of immunomodulation in the management of factor VIII inhibitors. Hematology Am Soc Hematol Educ Program (2006) 421-425
5. Escuriola Ettingshausen C., and Kreuz W. Role of von Willebrand factor in immune tolerance induction. Blood Coagul Fibrinolysis 16 Suppl 1 (2005) S27-S31
6. Colowick A., Bohn R., Avorn J., and Ewenstein B. Immune tolerance induction in hemophilia patients with inhibi- tors: costly can be cheaper. Blood 96 (2000) 1698-1702
7. Brackmann H., and Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 2 (1977) 933
8. Freiburghaus C., Berntorp E., Ekman M., Gunnarsson M., Kjellberg B., and Nilsson I. Tolerance induction using the Malmö treatment model 1982-1995. Haemophilia 5 (1999) 32-39
9. Mauser-Bunschoten E., Nieuwenhuis H., Roosendaal G., and van den Berg H. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 86 (1995) 983-988
10. Kreuz W., Ehrenforth S., Funk M., Auerswald G., Mentzer D., Joseph-Steiner J., et al. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia 1 (1995) 24-32
11. Kreuz W., Escuriola Ettingshausen C., Auerswald G., Heidemann P., Kemkes-Matthes B., Schneppenheim R., et al. Immune tolerance induction (ITI) in haemophilia A - patients with inhibitors - the choice of concentrate affecting success. Haematologica 86 Suppl 4 (2001) 16-22
12. Auerswald G., Spranger T., and Brackmann H. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 88 Suppl 9 (2003) 21-25
13. Gringeri A., Musso R., Mazzucconi M., Piseddu G., Schiavoni M., Pignoloni P., and Mannucci P. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of poor response. Haemophilia 13 (2007) 373-379
14. Astermark J., Morado M., Rocino A., van den Berg H., von Depka M., Gringeri A., et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 12 (2006) 363-371
15. DiMichele D., Hoots W., Pipe S., Rivard G., and Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 13 Suppl 1 (2007) 1-22
16. Escuriola Ettingshausen C., and Kreuz W. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia 12 Suppl 6 (2006) 102-106
17. Suzuki T., Arai M., Amano K., Kagawa K., and Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 76 (1996) 749-754
18. Saenko E., Shima M., Rajalakshmi K., and Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 269 (1994) 11601-11605
19. Behrmann M., Pasi J., Saint-Remy J., Kotitschke R., and Kloft M. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 88 (2002) 221-229
20. Kallas A., and Talpsep T. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients. Haemophilia 7 (2001) 375-380
21. Tagariello G., Zanotto D., Radossi P., Sartori R., Belvini D., and Salviato R. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates. Am J Hematol 82 (2007) 460-462
22. Inoue T., Shima M., Takeyama M., Matsumoto T., Nishiya K., Tanaka I., et al. Higher recovery of factor VIII (FVIII) with intermediate FVIII/von Willebrand factor concentrate than with recombinant FVIII in a haemophilia A patient with an inhibitor. Haemophilia 12 (2006) 110-113